This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

BTIG analyst Julian Harrison upgraded the rating for Aclaris Therapeutics, Inc. ACRS from Neutral to Buy and announced a price target of $8. Aclaris Therapeutics shares closed at $3.14 on Monday. See how other analysts view this stock.
HSBC analyst Wesley Brooks upgraded the rating for QuantumScape Corporation QS from Reduce to Hold and announced a price target of $5.3. QuantumScape shares closed at $4.73 on Monday. See how other analysts view this stock.
Evercore ISI Group analyst Cory Kasimov upgraded the rating for BioNTech SE BNTX from In-Line to Outperform and boosted the price target from $110 to $125. BioNTech shares closed at $101.87 on Monday. See how other analysts view this stock.
Canaccord Genuity analyst Matthew Lee upgraded Bank of Nova Scotia BNS from Hold to Buy and raised the price target from C$71 to C$84. See how other analysts view this stock.
Jefferies analyst Roger Song upgraded the rating for Aclaris Therapeutics, Inc. ACRS from Hold to Buy and raised the price target from $2 to $7. Aclaris Therapeutics shares closed at $3.14 on Monday. See how other analysts view this stock.

Considering buying BNTX stock? Here’s what analysts think:

Start Futures Trading Fast — with a $200 Bonus

Join Plus500 today and get up to $200 to start trading real futures. Practice with free paper trading, then jump into live markets with lightning-fast execution, low commissions, and full regulatory protection.